- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03398811
Abnormal Uterine Bleeding and Progestin-only Contraceptives
Predictors of Abnormal Uterine Bleeding in Progestin-only Contraceptives Users
The use of progestin-only methods of contraception has been increased obviously and progressively over the world in the last few years. Progestin-only contraception is an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns.
Progestogen-only pills are contraceptive pills that contain only synthetic progestogens (progestins) and do not contain estrogen . The progestin-only pill is recommended over regular birth control pills for women who are breastfeeding because the mini-pill does not affect milk production.
The most common progestin-only method used is the injectable depot medroxy-progesterone acetate which had been approved by Food and Drug Administration since 1992 . depot medroxy-progesterone acetate provides reliable, private, long-acting (three months) and reversible contraception. Users of depot medroxy-progesterone acetate don't need daily taking as well as it doesn't affect the intercourse by any mean.
The etonogestrel implant (Implanon) is a single-rod progestin contraceptive method placed subdermally in the inner aspect of upper non dependant arm for three years. Much evidence supports the safety, efficacy, reversibility and acceptability of this contraceptive method.
A common reason women choose to discontinue progestin-only contraception is dissatisfaction with its effects on uterine bleeding which occurs in a significant number of users. Information revealed from many clinical trials shows that abnormal uterine bleeding with progestin-only contraception ranging from 10 to 25 % at first year of use.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt, 71111
- Women Health Hospital - Assiut university
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women aged between 18-40 years.
- Women with more than 12 month postpartum.
- Women who had normal menstrual pattern (cycle from 21 - 35 days with a same cycle length variation of no more than 5 days, bleeding days from 2-7 days and number of sanitary pads not more than 3 pads without blood clots or flooding of blood).
- Women wanted to use DMPA, etonogestrel subdermal implant or POPs only for pregnancy prevention for at least 1 year.
Exclusion Criteria:
- Women on any anticoagulant therapy.
- Women who had a history of uterine, cervical or ovarian pathology.
- Women who had uterine bleeding disturbance (including amenorrhea) before recruitment.
- Women received DMPA injection within the previous 9 months except they had three spontaneous regular menstrual cycles.
- Severely anemic women (hemoglobin < 8gm/dl).
- Women with any contraindications for POCs following the WHO eligibility (Altshuler AL et al., 2015).
- Women refused to participate in the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group I "the depot medroxy-progesterone acetate group"
where they will use Depot Medroxyprogesterone Acetate 150 mg injection every 3 month,
|
Injection every 3 months
|
Group II "Implanon group"
where they will have Implanon (etonogestrel implant) 68 mg implant
|
68 mg implant
|
group III (cerazette group)
where they are using Cerazette pills (desogestrel 75 µg l) one pill every day for 28 days without pill-free interval.
|
one pill every day for 28 days without pill-free interval.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of women developed vaginal bleeding
Time Frame: 12 month
|
12 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Hemorrhage
- Uterine Hemorrhage
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Progestins
- Contraceptive Agents, Male
- Progesterone
- Medroxyprogesterone Acetate
- Medroxyprogesterone
- Desogestrel
- Etonogestrel
Other Study ID Numbers
- POCU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Montefiore Medical CenterSociety of Family PlanningCompletedContraception | Breastfeeding | Postpartum ContraceptionUnited States
Clinical Trials on Depot medroxy-progesterone acetate
-
Assiut UniversityCompletedComplications of DMPA Injectable ContraceptivesEgypt
-
AbbottFraktal.com.pl; Med-net.plCompletedLower Urinary Tract Symptoms | Advanced Prostate CancerPoland, Ukraine
-
Ewha Womans University Mokdong HospitalSamsung Medical Center; Ministry of Health & Welfare, Korea; Han Wha Pharma Co...Unknown
-
Aswan University HospitalUnknownPlacenta PreviaEgypt
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
Erasmus Medical CenterOrganonCompleted
-
TakedaRecruitingCentral Precocious PubertyChina
-
University of ChicagoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingPolycystic Ovary Syndrome | Obstructive Sleep ApneaUnited States
-
Repros Therapeutics Inc.CompletedUterine LeiomyomataPoland
-
National Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7United States